- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…BioSpace · 3d ago↗ source
- STAT+: Advocates say federal funding is being cut from groups fighting HIVThe administration is shifting some funding to states, but community groups are set to lose out.STAT · 3d ago↗ source
- Crystalys mines $130M series B to push gout drug through phase 3Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.<br>